Food and Drug Administration (FDA) in 2017 for the treatment of type 2 diabetes to improve blood sugar control and reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [1]
Glucagon helps signal the liver and adipose tissue to release stored energy
Its signaling complexity (triple agonism) imposes heightened methodological vigilance: systematic glycemic monitoring to detect any paradoxical hyperglycemia linked to the glucagon arm, regular hepatic panel given the lipolytic effect, and lean mass tracking to quantify the share of weight loss linked to muscle depletion under severe caloric restriction
Phase 2 trial dosage groups and weight loss results The Phase 2 trial randomized 338 adults with obesity (BMI 30 or higher, or BMI 27-30 with at least one weight-related condition) into seven groups
Effective epilepsy prevention: Lamictal calms erratic brain activity, reducing the frequency and intensity of seizures
Patients can be reassured that the combination does not inherently increase haemorrhagic complications beyond the baseline risk associated with anticoagulation therapy alone
